Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1049 Y-27632 2HCl 14 mg/mL 64 mg/mL <1 mg/mL
S1459 Thiazovivin <1 mg/mL 15 mg/mL <1 mg/mL
S1573 Fasudil (HA-1077) HCl 65 mg/mL 5 mg/mL <1 mg/mL
S1474 GSK429286A <1 mg/mL 87 mg/mL 4 mg/mL
S7195 RKI-1447 <1 mg/mL 65 mg/mL <1 mg/mL
S7687 GSK269962A HCl <1 mg/mL 100 mg/mL 6 mg/mL
S8226 Netarsudil (AR-13324) 2HCl 54 mg/mL 20 mg/mL 2 mg/mL
S7935 Y-39983 HCl 63 mg/mL 63 mg/mL 2 mg/mL
S8448 ZINC00881524 (ROCK inhibitor) <1 mg/mL 76 mg/mL 3 mg/mL
S7936 KD025 (SLx-2119) <1 mg/mL 90 mg/mL <1 mg/mL
S7995 Ripasudil (K-115) hydrochloride dihydrate 79 mg/mL 26 mg/mL 5 mg/mL
S8208 Hydroxyfasudil (HA-1100) HCl 60 mg/mL 68 mg/mL <1 mg/mL
S8489 GSK180736A (GSK180736) <1 mg/mL 73 mg/mL 3 mg/mL
S7563 AT13148 <1 mg/mL 62 mg/mL <1 mg/mL

Isoform-specific Inhibitors

Catalog No. Information Product Use Citations Product Validations

Y-27632 2HCl

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.



Thiazovivin is a novel ROCK inhibitor with IC50 of 0.5 μM in a cell-free assay, promotes hESC survival after single-cell dissociation.


Fasudil (HA-1077) HCl

Fasudil(HA-1077), a potent and selective inhibitor of Rho kinase, displays less potent inhibiton over PKA, PKG, PKC and MLCK with Ki of 1.6, 1.6, 3.3, and 36 μM in cell-free assays, respectively.



GSK429286A is a selective inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 63 nM, respectively.



RKI-1447 is a potent inhibitor of ROCK1 and ROCK2, with IC50 of 14.5 nM and 6.2 nM, respectively, has anti-invasive and antitumor activities.


GSK269962A HCl

GSK269962 is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.


Netarsudil (AR-13324) 2HCl

Netarsudil (a.k.a. AR-13324) is ROCK inhibitor with Ki value of 0.2-10.3 nM. It is currently in clinical trials for the treatment of glaucoma and ocular hypertension.


Y-39983 HCl

Y-39983 is a selective rho-associated protein kinase(ROCK) inhibitor with an IC50 of 3.6 nM.


ZINC00881524 (ROCK inhibitor)

ZINC00881524 is a ROCK inhibitor.


KD025 (SLx-2119)

KD025 is an orally available, and selective ROCK2 inhibitor with IC50 and Ki of 60 nM and 41 nM, respectively. Phase 2.


Ripasudil (K-115) hydrochloride dihydrate

Ripasudil (K-115) hydrochloride dihydrate is potent ROCK inhibitor with IC50 of 51 nM and 19 nM for ROCK1 and ROCK2, respectively, used for the treatment of glaucoma and ocular hypertension.


Hydroxyfasudil (HA-1100) HCl

Hydroxyfasudil (HA-1100), an active metabolite of fasudil hydrochloride, is a specific Rho-kinase(ROCK) inhibitor with IC50 values of 0.73 μM and 0.72 μM for ROCK1 and ROCK2, respectively.


GSK180736A (GSK180736)

GSK180736A, developed as a Rho-associated, coiled-coil-containing protein kinase inhibitor, binds to GRK2(G protein-coupled receptor kinase 2) with logIC50 pf -6.6 (logIC50 -4.0 for GRK5 and >-3 for GRK1); ≥400-fold selective for GRK2 over both GRK1 and GRK5.



AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

Tags: ROCK inhibition | ROCK activity | ROCK activation | Rho kinase inhibition | Rho kinase activation | Rho kinase activity | ROCK phosphorylation | ROCK signaling pathway | Rho kinase assay | Rho kinase signaling pathway | ROCK inhibitors for glaucoma | ROCK inhibitor review